Share Email Print
cover

Proceedings Paper

In situ photoimmunotherapy for melanoma: an ongoing phase I clinical trial
Author(s): Mark F. Naylor; Robert E. Nordquist; T. Kent Teague; Lisa A. Perry; Wei R. Chen
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

In situ Photoimmunotherapy (ISPI) was developed to treat metastatic tumors using a combination of phototherapy and immunotherapy. It utilizes local intervention through photothermal destruction of existing solid tumors and through immune response modifier to elicit host anti-tumor responses. Such combination in pre-clinical studies has shown promise in cancer treatment by eradicating the primary tumors and also controlling metastases at distant sites. ISPI has been used in our preliminary clinical studies for melanoma patients and the outcome has been extremely encouraging. In 2006, we began enrolling patients in a new phase I immunotherapy trial for advanced cutaneous melanoma. This trial is based on our previous results which indicated that we had developed an effective treatment for advanced melanoma. Of the first six patients treated, (4 stage IV, and 2 surgically unresectable stage III), 2 of the stage IV patients are still alive, one tumor free, and one with a possible treatable recurrence after 2 1/2 years. We have also discovered that recurrences of the skin cancer can be retreated by the same technique and that treatment seems to blunt the virulence of the disease and make it more treatable. These initial results indicate that ISPI probably will have the ability to prolong survival in selected cases of advanced melanoma, and potentially cure a significant percentage of treated patients.

Paper Details

Date Published: 13 February 2007
PDF: 9 pages
Proc. SPIE 6438, Biophotonics and Immune Responses II, 643807 (13 February 2007); doi: 10.1117/12.711217
Show Author Affiliations
Mark F. Naylor, Univ. of Oklahoma College of Medicine (United States)
Robert E. Nordquist, Advanced Cancer Therapies L.L.C. (United States)
T. Kent Teague, Univ. of Oklahoma College of Medicine (United States)
Univ. of Oklahoma College of Pharmacy (United States)
Oklahoma State Univ. Ctr. for Health Sciences (United States)
Lisa A. Perry, Univ. of Oklahoma College of Medicine (United States)
Wei R. Chen, Univ. of Central Oklahoma (United States)


Published in SPIE Proceedings Vol. 6438:
Biophotonics and Immune Responses II
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top